Wall Street brokerages expect Viking Therapeutics Inc (NASDAQ:VKTX) to report ($0.11) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings of ($0.22) per share in the same quarter last year, which suggests a positive year over year growth rate of 50%. The business is scheduled to issue its next earnings results on Wednesday, November 14th.
On average, analysts expect that Viking Therapeutics will report full year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.41). For the next financial year, analysts forecast that the business will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.55) to ($0.39). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02).
Shares of VKTX traded down $0.75 during mid-day trading on Friday, hitting $14.51. 55,651 shares of the company’s stock were exchanged, compared to its average volume of 2,877,918. Viking Therapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $24.00. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -18.81 and a beta of 2.81.
In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. Boxer Capital LLC lifted its position in Viking Therapeutics by 17.7% in the second quarter. Boxer Capital LLC now owns 3,750,000 shares of the biotechnology company’s stock valued at $35,588,000 after purchasing an additional 564,000 shares during the period. BlackRock Inc. lifted its position in Viking Therapeutics by 681.0% in the second quarter. BlackRock Inc. now owns 2,938,645 shares of the biotechnology company’s stock valued at $27,888,000 after purchasing an additional 2,562,356 shares during the period. Janus Henderson Group PLC acquired a new stake in Viking Therapeutics in the second quarter valued at about $19,552,000. Millennium Management LLC lifted its position in Viking Therapeutics by 99.1% in the first quarter. Millennium Management LLC now owns 1,399,370 shares of the biotechnology company’s stock valued at $6,115,000 after purchasing an additional 696,398 shares during the period. Finally, Opaleye Management Inc. lifted its position in Viking Therapeutics by 9.0% in the second quarter. Opaleye Management Inc. now owns 1,200,000 shares of the biotechnology company’s stock valued at $11,388,000 after purchasing an additional 99,200 shares during the period. Hedge funds and other institutional investors own 53.22% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.